Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Prot #CX-839-012: A Phase 1b/2, Open label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with the CDK4/6 Inhibitor Palbociclib in Patients with Advanced or Metastatic Solid Tumors
Chae, Young Kwang
(PD/PI)
Medicine, Hematology Oncology Division
Project
:
Research project
Overview
Project Details
Status
Finished
Effective start/end date
7/21/20
→
7/21/23
Funding
Calithera Biosciences, Inc.
(Prot #CX-839-012)
View all
View less